{"filings":[{"id":555396,"accession_number":"0001193125-26-232712","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-05-20T20:32:56+00:00","items":["5.07"],"status":"ready","headline":"BLCO shareholders re-elect all 10 directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected, each with ~331.5M votes for, ~4.2M against, ~11.5M broker non-votes.","Advisory vote on executive compensation passed: 328.1M for, 0.8M against, 6.9M abstain.","PricewaterhouseCoopers LLP ratified as independent auditor: 343.3M for, 4.0M withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96351,"accession_number":"0001860742-26-000060","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 2026 revenue $1.244B (+9% YoY), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.244B, up 9% reported and 6% constant currency YoY; GAAP net loss narrowed to $71M from $212M.","Adjusted EBITDA (non-GAAP) $189M vs $98M prior year; adjusted EPS $0.05 vs -$0.15.","Raising 2026 revenue guidance to $5.42B-$5.52B (was $5.375B-$5.475B) and Adj. EBITDA ex-IPR&D to $1.01B-$1.06B.","Pharmaceuticals segment grew 12% constant currency; MIEBO (+33%) and XIIDRA (+30%) led growth.","Vision Care +5% constant currency; Surgical +1% constant currency; double-digit growth in daily SiHy lenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":1244000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110175,"accession_number":"0001860742-26-000006","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4 rev $1.405B (+10%), net loss $58M; guides FY2026 rev $5.375B-$5.475B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.405B (+10% reported, +7% constant currency); FY revenue $5.101B (+6% reported, +5% constant currency).","Q4 GAAP net loss $58M (vs $3M loss in Q4 2024); FY net loss $360M (vs $317M).","Q4 adjusted EBITDA $326M (+$67M YoY); adjusted EPS $0.32 (vs $0.25). FY adjusted EBITDA $858M; adjusted EPS $0.43.","Segment: Vision Care $778M (+8%), Surgical $249M (+8%), Pharma $378M (+16%); MIEBO sales $112M in Q4.","FY2026 guidance: revenue $5.375B-$5.475B (5-7% constant currency growth); adjusted EBITDA ex-IPR&D $1.000B-$1.050B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":5101000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110174,"accession_number":"0000950103-26-000051","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb completes $2.8B term loan refinancing; margin cut up to 0.50%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Fourth Amendment providing $2,802,125,000 Replacement Term Loans maturing January 15, 2031.","Proceeds used to refinance existing term B loans due 2028 ($1.0B+) and 2031, extending maturity of 2028 tranche.","Applicable margin reduced by 0.50% (SOFR loans) to 3.75% and by 0.25% (base rate loans) to 2.75%.","Amortization set at 1.00% per annum with first installment due June 30, 2026.","Refinancing closed on January 2, 2026, as previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126732,"accession_number":"0001860742-25-000035","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K/A","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb assigns new directors Alfonso, Collis to board committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eduardo C. Alfonso, MD appointed to Science and Technology Committee, effective Jan 1, 2026.","Steven H. Collis appointed to Talent and Compensation Committee, effective Jan 1, 2026.","Both were appointed to the Board effective same date as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126736,"accession_number":"0001193125-25-322866","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bausch + Lomb appoints Eduardo Alfonso, MD and Steven Collis to board, effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eduardo C. Alfonso, MD, and Steven H. Collis appointed to Bausch + Lomb board, effective Jan 1, 2026.","Appointments fill vacancies left by Brett Icahn and Gary Hu who departed in August 2025; board will have 10 directors.","Both new directors are independent under NYSE and TSX rules; no committee assignments announced.","Alfonso is a prominent ophthalmologist; Collis is former CEO of AmerisourceBergen (Fortune 10)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126735,"accession_number":"0000950103-25-016088","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb refinances $2.8B in term loans, cuts margins and extends maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Replacement Term Loans of $2,802M allocated to refinance all outstanding term B loans due 2028 and 2031.","Margin reduced by 0.50% on the existing 2031 term loans and 0.25% on the 2028 term loans; new margins at SOFR+3.75% or ABR+2.75%.","Maturity of the 2028 loans extended from Sept 29, 2028 to Jan 15, 2031, matching the existing 2031 maturity.","Transaction anticipated to close in Q1 2026, subject to customary conditions.","Net interest expense expected to decrease due to lower applicable margins on the refinanced debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126734,"accession_number":"0000950103-25-014656","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bausch + Lomb targets 5-7% revenue CAGR, ~23% EBITDA margin; pipeline peak sales ~$7B","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Targets 5-7% constant currency revenue CAGR 2025-2028.","Adjusted EBITDA margin (excl. Acq. IPR&D) target of ~23% in 2028.","Double-digit adjusted EPS growth (excl. Acq. IPR&D) expected 2026-2028.","Pipeline products projected peak sales of ~$7 billion; key launches include ELIOS MIGS (US 2H 2026) and PreserVision AREDS3 (1H 2026).","Net leverage target of ~3.5x by end of 2028; 2025 guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126733,"accession_number":"0001860742-25-000021","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q3 revenue $1.28B (+7% YoY); narrows FY adjusted EBITDA guidance to $870M-$910M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.281B, up 7% reported (6% constant currency); Vision Care +8%, Surgical +4%, Pharmaceuticals +8%.","GAAP net loss $28M ($0.08 loss per share) vs net income $4M ($0.01 EPS) in Q3 2024.","Adjusted EBITDA excluding acquired IPR&D $243M, up from $227M; adjusted EPS excl. IPR&D $0.18 vs $0.17.","FY 2025 revenue guidance reaffirmed at $5.05B-$5.15B; adjusted EBITDA guidance low end raised $10M to $870M-$910M.","Cash from operations $137M vs $154M; CEO cites pipeline and investor day as upcoming catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3696000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143523,"accession_number":"0001860742-25-000019","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.02","5.02","7.01","9.01"],"status":"ready","headline":"Bausch+Lomb's Icahn directors resign after agreement terminates","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Icahn and Gary Hu resigned from BLCO board effective August 14, 2025.","Resignations triggered by Icahn group's net long position in Bausch Health falling below threshold in the 2022 Director Appointment Agreement.","The Amended and Restated Director Appointment and Nomination Agreement terminated automatically on that date.","Resignations not due to any disagreement with Bausch+Lomb, per filing.","Chairman and CEO Brent Saunders thanked the departing directors for their service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143522,"accession_number":"0001860742-25-000016","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q2 revenue $1.278B, GAAP loss narrows to $62M, raises FY2025 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.278B, +5% as reported (+3% constant currency); Vision Care +8%, Surgical +3%, Pharma flat.","GAAP net loss $62M ($0.18 loss per share) vs $151M loss ($0.43) a year ago; adjusted net income $25M ($0.07 adjusted EPS).","Adjusted EBITDA $191M vs $209M prior year; Adj EBITDA ex-IPR&D $192M vs $212M.","Raised FY2025 guidance: revenue $5.05B-$5.15B (prior $5.0B-$5.1B), constant currency growth ~5-7%; Adj EBITDA ex-IPR&D $860M-$910M.","Resumed full production of enVista IOLs following recall; dry eye portfolio reached ~$1B trailing revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2415000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143521,"accession_number":"0000950103-25-009183","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch + Lomb CEO amends employment agreement; PSUs now tied to share price and EBITDA goals through 2029","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brenton Saunders gave up 'good reason' severance right tied to spin-off timing from Bausch Health.","Amended PSUs vest Feb 23, 2029; payout range 120%-330% of target based on share-price hurdles ($26.57-$39.06).","Cumulative Adjusted EBITDA performance modifier for FY2025-2028 can adjust payout by -40% to +40%.","PSU payout also subject to Saunders' continued employment through the performance period.","Full text of amendments will be filed in Q3 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161710,"accession_number":"0001193125-25-149726","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb closes €675M notes offering and $2.325B term loan refinancing, extends maturities to 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€675M senior secured floating rate notes due Jan 15, 2031, at EURIBOR + 3.875%, priced at 99.5%.","$2.325B term B loans due 2031 at SOFR+4.25% or base+3.25%; $800M revolver replaced $500M revolver.","Proceeds used to repay 2027 term A and B loans and revolver; first-lien net leverage covenant raised to 5.75:1 (stepping down).","Term loans amortize at 1% per annum; first payment Sept 30, 2025.","Notes secured on first-priority basis by collateral also securing existing credit and senior secured notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161709,"accession_number":"0000950103-25-007603","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb prices €675M senior secured notes, upsizes term loan to $2.325B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuers priced €675M senior secured floating rate notes due 2031 at 99.500% of principal, upsized from €600M.","New $2.325B term B loan facility (Term SOFR + 4.25%) upsized from $2.2B; $800M revolver also planned.","Proceeds will repay existing revolver, refinance term A and B loans due 2027, and pay fees.","Notes offering and new credit facilities expected to close on June 26, 2025, subject to conditions.","Notes are guaranteed by Bausch + Lomb and secured by same assets as existing senior secured notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161708,"accession_number":"0000950103-25-007189","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb launches €600M notes offering and $2.2B term loan refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Subsidiaries launch €600M senior secured floating rate notes offering.","New $2.2B term B loan facility and $800M revolving credit facility planned.","Proceeds to repay existing revolver and refinance term A and B loans due 2027.","Notes offering not contingent on new credit facilities; secured by same collateral.","Transactions subject to market conditions; no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161707,"accession_number":"0001193125-25-124034","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bausch + Lomb shareholders elect all 10 director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with >99% support; broker non-votes ~8.4M.","Say-on-pay advisory vote approved: 326.9M for, 11.6M against, 1M abstain.","PricewaterhouseCoopers LLP ratified as independent auditor with 346.4M for, 1.5M withheld.","Meeting held May 21, 2025; all proposals carried as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161706,"accession_number":"0000950103-25-006266","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"B+L reports majority shareholder BHC enters standstill pacts with Icahn, Paulson, Kavanagh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Icahn, Paulson, and Kavanagh groups agree to resign from BHC/B+L boards if they engage in Specified Actions like proxy contests or buying >19.99% of BHC.","Icahn Group waives rights under the 2022 B+L DANA, including the right to designate a replacement director.","BHC commits to vote its B+L shares for management nominees from these groups as long as no Specified Action occurs.","B+L is not a party to the Letter Agreements; full terms are in BHC's Form 8-K filed May 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161705,"accession_number":"0001860742-25-000007","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 net loss $212M; enVista recall cuts FY adj. EBITDA guidance by ~$65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.137B (+3% reported, +5% constant currency) vs $1.099B YoY.","GAAP net loss $212M ($0.60/share); adjusted net loss $54M ($0.15/share).","Adjusted EBITDA excl. acquired IPR&D $126M, down from $180M YoY.","enVista IOL voluntary recall impacts: ~$55M revenue, ~$65M adj. EBITDA hit in FY 2025.","FY 2025 guidance: revenue $5.0B-$5.1B (previously $4.95B-$5.05B); adj. EBITDA $850M-$900M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1137000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179809,"accession_number":"0001860742-25-000003","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q4 revenue up 11% CC; FY GAAP loss widens; guides 2025 revenue ~$5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.28B, up 9% reported and 11% constant currency, with growth across all segments.","FY GAAP net loss attributable $317M vs $260M loss in 2023; adjusted net income $204M vs $258M.","Adjusted EBITDA ex Acquired IPR&D FY $878M (+$140M); Q4 $259M (+$28M).","2025 guidance: revenue $4.95B-$5.05B (~5.5%-7.5% CC growth); Adj. EBITDA $900M-$950M; FX headwinds ~$100M revenue.","Dry eye portfolio approaching $1B annual revenue; contact lens double-digit Q4 growth; XIIDRA/MIEBO driving pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":4791000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196570,"accession_number":"0000950103-24-015809","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bausch + Lomb borrows $400M in incremental term loans; matures 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $400M in Second Incremental Term Loans under credit agreement dated May 10, 2022.","Term loans mature May 10, 2027; amortize quarterly starting Q1 2025.","Interest rate: base rate + 2.25% or term SOFR + 3.25%, at borrower's option.","Proceeds used to repay revolving credit facility and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196569,"accession_number":"0001860742-24-000016","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).","Adjusted EBITDA $212M ($227M ex-IPR&D) vs $187M YoY, driven by broad-based sales growth.","Pharmaceuticals revenue surged 76% to $306M on XIIDRA acquisition and MIEBO launch.","FY2024 revenue guidance raised to $4.725-4.825B (prior $4.70-4.80B); adjusted EBITDA outlook unchanged.","Cash flow from operations $154M, up from $48M YoY, aided by gross profit and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":3511000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212875,"accession_number":"0001860742-24-000011","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q2 revenue $1.216B (+17% YoY); GAAP net loss $151M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.216B, up 17% reported and 20% constant currency vs Q2 2023.","GAAP net loss attributable to BLCO $151M; adjusted EPS $0.13 (vs $0.18 a year ago).","Pharmaceuticals segment revenue surged 60% YoY to $310M, driven by XIIDRA acquisition and MIEBO launch.","Raised FY2024 revenue guidance to $4.7-4.8B (prev $4.6-4.7B) and adjusted EBITDA to $850-900M.","Adjusted EBITDA (non-GAAP) $209M, up from $179M in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2315000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231934,"accession_number":"0001193125-24-149259","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Shareholders approve 14M share increase to omnibus plan, elect all director nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2022 Omnibus Incentive Plan, adding 14M authorized common shares.","All 10 director nominees elected with >99% votes cast in favor; no contested seats.","Advisory vote on executive compensation passed with 328.7M for vs 15.9M against (95.4% support).","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year.","Approximately 347.6M shares voted on auditor ratification; absent broker non-votes on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231933,"accession_number":"0001860742-24-000007","cik":1860742,"company_name":"Bausch & Lomb Corp","ticker":"BLCO","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch + Lomb Q1 revenue $1.099B (+18% YoY); raises FY constant-currency growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss attributable widened to $167M from $90M; adjusted EBITDA rose to $180M from $141M.","Vision Care revenue $635M (+8% reported, +11% constant currency); Surgical $197M (+8%); Pharmaceuticals $267M (+66% on XIIDRA/MIEBO).","Raises FY constant-currency revenue growth guidance to 13-15% from 12-14%; revenue range now $4.600-$4.700B.","Adjusted EPS (non-GAAP) $0.07 vs $0.10; GAAP EPS ($0.48) vs ($0.26).","Cash from operations $41M vs use of $56M in Q1 2023; foreign-exchange headwind estimated at $90M for FY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":1099000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5590490006.900763,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}